Donate

Pamorelin (Trelstar) Now Available in the Philippines

Pamorelin (Trelstar® )is going to become available in the Philippines. Pamorelin, and Decapeptyl® will be made available to urologists and oncologists who treat men with advanced prostate cancer. It will be available in one, three and six month formulations. Pamorelin is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH). It is designed to chemically [...]

FDA Clears a Six-Month Trelstar Formulation for the Palliative Treatment of Advanced Prostate Cancer

Watson Pharmaceuticals announced that it has received approval from the FDA for its new six-month intramuscular formulation, Trelstar, a (triptorelin pamoate for injectable suspension) 22.5 mg. Trelstar 22.5 mg is a gonadotropin releasing hormone (GnRH) agonist used for the palliative treatment of advanced prostate cancer. […]

The FDA Has Approved TRELSTAR(R) 22.5 mg, The First 6-Month GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer

Watson Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Trelstar – 22.5 mg (triptorelin pamoate for injectable suspension) at a dosage which will be required only to be administered twice a year. […]

Go to Top